Anita Nelson, MD, discusses the FDA's approval extending etonogestrel implant use to 5 years and the new REMS certification clinicians must complete by February 23, 2027.
|Articles|August 20, 2018
Should Partners of Women with Bacterial Vaginosis be Treated?
Advertisement
While initial cure rates for bacterial vaginosis (BV) approach 80%, 2 out of 3 women experience a recurrence within 6 months of treatment. Since BV is not currently considered a sexually transmitted infection, treatment guidelines do not include treating partners of women with BV. How does this approach to management align with epidemiologic data and current trial results?
In this supplement, Christina Muzny, MD, MSPH examines the issue of BV re-infection and partner treatment, to include:
- Prevalence and associated complications of BV
- Current CDC STD Treatment Guidelines
- Epidemiologic data that supports the sexual transmission of BV
- Methodological shortcomings of prior partner treatment trials
Read this supplement to learn more about treating partners of women with BV.
Supported by:
Lupin Pharmaceuticals
Advertisement
Related to this article
Placentas from older mothers held less NAD+, and in aged pregnant mice, nicotinamide riboside or the CD38 inhibitor 78c restored placental NAD+ and improved fetal growth.
Hugh Taylor, MD, outlines a stepwise approach to endometriosis therapy, from first-line oral contraceptives to oral GnRH antagonists for progestin-resistant patients.
Hosted by Calbeth C. Alaribe, DMSc, MPH, PA-C, CPCHE, the monthly series brings clinicians, researchers, innovators, advocates, and other voices across women’s health into conversations that rarely happen in the same room.
A new book from Sameena Rahman, MD, reclaims "brown girls' disease" as a lens for examining how dismissal—of conditions, anatomy, and patients—undermines sexual medicine care for all women.
Menopause proteomics were consistently associated with inflammatory brain aging and Alzheimer’s dementia risk across nearly 15,000 women in a new study published in Nature Medicine.
The FDA approved an IDE allowing Mercy BioAnalytics to evaluate its Evident blood-based ovarian cancer screening test in the prospective pivotal SOARA study of average-risk women.
Sameena Rahman, MD, discusses how digital symptom trackers can shorten PMOS diagnostic delays and support earlier cardiometabolic care.
Advertisement
Advertisement
Trending on Contemporary OB/GYN
1
Contemporary OB/GYN launches 'Missed & Dismissed' podcast to explore diagnostic gaps in women's health
2
Q&A: Anita Nelson, MD, on etonogestrel implant's 5-year approval and REMS certification
3
Menopause proteomic scores associated with cognitive aging, dementia risk
4
CD38 is tied to age-related placental NAD+ decline in preclinical study
5